Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new awareness campaign for pneumococcal pneumonia vaccination. Toward the end ...

Just a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has reported positive trial results in children that will ramp up the pressure on Pfizer and ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's success in 2020 ...

Two words come to mind for Elizabeth Banks after her showdown with shingles: "Not fun." ...

Prevnar, Pfizer's blockbuster pneumococcal vaccine, faces competition from Merck 's Capvaxive, while Ibrance, the company's leading breast cancer treatment, is under pressure from Novartis ' Kisqali.